Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

U.S., Europe Differ On Use Of Avastin

by Michael McCoy
December 20, 2010 | A version of this story appeared in Volume 88, Issue 51

FDA plans to remove the breast cancer indication for Genentech’s Avastin after concluding the drug is not safe and effective for that use. In contrast, the European Medicines Agency has concluded that the benefits of Avastin outweigh its risks. The determinations, both announced on Dec. 16, are for Avastin with paclitaxel. Genentech, a Roche unit, says it will request a hearing to contest FDA’s decision. FDA approved the Avastin-paclitaxel combination for breast cancer in February 2008 under an accelerated approval program. With sales last year of about $6.7 billion, Avastin is Roche’s biggest-selling drug, although breast cancer is just one of several indications.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.